Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Anichini, A.
814  Ergebnisse:
Personensuche X
?
1

123P A phase II study of nivolumab (N) plus ipilimumab (I) ..:

Di Giacomo, A.M. ; Rossi, G. ; Calabro, L....
Immuno-Oncology and Technology.  20 (2023)  - p. 100595 , 2023
Link: https://doi.org/10.1016/..
 
?
2

26P Liquid biopsy as promising source of plasma extracellul..:

Huber, V. ; Mereu, A. ; Lalli, L....
Immuno-Oncology and Technology.  20 (2023)  - p. 100495 , 2023
Link: https://doi.org/10.1016/..
 
?
3

27P Peripheral biomarker analysis in patients with advanced..:

Sgambelluri, F. ; Giannatempo, P. ; Stellato, M....
Immuno-Oncology and Technology.  20 (2023)  - p. 100496 , 2023
Link: https://doi.org/10.1016/..
 
?
4

12P Multi-omics correlation with clinical outcome in metast..:

Di Giacomo, A.M. ; Noviello, T. ; Caruso, F.P....
Immuno-Oncology and Technology.  16 (2022)  - p. 100117 , 2022
Link: https://doi.org/10.1016/..
 
?
5

PEOPLE (NCT03447678), a first-line phase II pembrolizumab t..:

Lo Russo, G. ; Sgambelluri, F. ; Prelaj, A....
ESMO Open.  7 (2022)  6 - p. 100645 , 2022
Link: https://doi.org/10.1016/..
 
?
6

Maintaining therapeutic continuity in adolescent psychiatri..:

Vita, G. De ; Terrinoni, A. ; Santo, F. Di...
European Psychiatry.  64 (2021)  S1 - p. S94-S94 , 2021
Link: https://doi.org/10.1192/..
 
?
7

Two patients with acute meningoencephalitis concomitant wit..:

Bernard‐Valnet, R. ; Pizzarotti, B. ; Anichini, A....
European Journal of Neurology.  27 (2020)  9 - p. , 2020
Link: https://doi.org/10.1111/..
 
?
8

Anticancer innovative therapy: Highlights from the ninth an..:

Volpari, T. ; De Santis, F. ; Bracken, A.P....
Cytokine & Growth Factor Reviews.  51 (2020)  - p. 1-9 , 2020
Link: https://doi.org/10.1016/..
 
?
9

Correction to: NFATc2 is an intrinsic regulator of melanoma..:

Perotti, V. ; Baldassari, P. ; Molla, A....
Oncogene.  38 (2019)  19 - p. 3763-3764 , 2019
Link: https://doi.org/10.1038/..
 
?
10

First survival outcomes and additional secondary analyses f..:

Necchi, A. ; Bandini, M. ; Gallina, A....
European Urology Supplements.  18 (2019)  1 - p. e1517 , 2019
Link: https://doi.org/10.1016/..
 
?
11

Cabozantinib (CABO) plus durvalumab (DURVA) in patients wit..:

Raggi, D. ; Giannatempo, P. ; Anichini, A....
European Urology Supplements.  17 (2018)  2 - p. e1150 , 2018
Link: https://doi.org/10.1016/..
 
?
12

Peculiar: An open label, multicenter, single-arm, phase 2 s..:

Necchi, A. ; Mariani, L. ; Anichini, A....
European Urology Supplements.  17 (2018)  2 - p. e1149 , 2018
Link: https://doi.org/10.1016/..
 
?
13

Innovative Therapy, Monoclonal Antibodies and Beyond:

Di Nicola, M. ; Apetoh, L. ; Bellone, M....
Cytokine & Growth Factor Reviews.  38 (2017)  - p. 1-9 , 2017
Link: https://doi.org/10.1016/..
 
?
14

Pembrolizumab and nanoparticle albumin bound paclitaxel (na..:

Necchi, A. ; Mariani, L. ; Anichini, A....
European Urology Supplements.  16 (2017)  10 - p. e2796 , 2017
Link: https://doi.org/10.1016/..
 
?
15

APACHE: An open label, randomized, phase 2 study of the ant..:

Necchi, A. ; Mariani, L. ; Anichini, A....
European Urology Supplements.  16 (2017)  3 - p. e373-e374 , 2017
Link: https://doi.org/10.1016/..
 
1-15